title: Novel biological treatments for systemic lupus erythematosus: current and future modalities.
abstract: Current treatments for systemic lupus erythematosus (SLE) are effective in reducing morbidity and mortality but are not specific and have severe adverse effects. Based on understanding of the different dysregulated immunological pathways involved in SLE pathogenesis, specific targeted therapies were developed. This review presents the current and the near-future novel biological immune targeted treatments, such as B cell-targeted therapy, cytokine blockade, peptide-based treatments and other novel treatments for SLE.
authors.affiliation: Department of Medicine B, Kaplan Medical Center, Rehovot, affiliated with Hebrew University-Hadassah Medical School, Jerusalem, Israel.
authors.forename: Shira
authors.initials: S
authors.lastname: Bezalel
authors.forename: Ilan
authors.initials: I
authors.lastname: Asher
authors.forename: Daniel
authors.initials: D
authors.lastname: Elbirt
authors.forename: Zev Moshe
authors.initials: ZM
authors.lastname: Sthoeger
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D053264:B-Cell Activating Factor / Q000097:blood; D001402:B-Lymphocytes / Q000276:immunology; D001691:Biological Therapy / Q000379:methods*; D016503:Drug Delivery Systems; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*; D009841:Oligonucleotides / Q000627:therapeutic use; D000069283:Rituximab; D013601:T-Lymphocytes / Q000187:drug effects; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D053264:B-Cell Activating Factor; D009841:Oligonucleotides; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13; C448700:epratuzumab; D000069283:Rituximab; C511911:belimumab; C094104:abetimus